SCHEMBL13779986

SCHEMBL13779986

CC1(C)c2cc(-c3ccc(N(c4ccccc4)c4ccccc4)cc3)ccc2-c2cc3c(cc21)-c1ccc(-c2ccc(N(c4ccccc4)c4ccccc4)cc2)cc1C3(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PDK2 Q15119 13/20 0.39
MEN1 O00255 1/20 0.35
CRHBP P24387 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
CRHR2 Q13324 1/20 0.35
TLR9 Q9NR96 1/20 0.35
PGR P06401 2/20 0.33
TDP2 O95551 1/20 0.33
PARP10 Q53GL7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12954606 1.00 ALDH1A1 (0.40) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL16169852 0.97 ALDH1A1 (0.38) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL13907766 0.97 ALDH1A1 (0.38) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL9971805 0.97 PDK2 (0.41) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL10014449 0.95 PDK2 (0.42) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL13779992 0.95 ALDH1A1 (0.39) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL10018637 0.95 ALDH1A1 (0.39) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL15496104 0.95 PDK2 (0.43) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL15836302 0.94 PDK2 (0.45) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4
SCHEMBL20799810 0.94 PDK2 (0.40) ALDH1A1L3MBTL1KDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090179551-A1 Organic Electroluminescent Compounds and Display Device Using the Same GRACEL DISPLAY INC. (KP) 2009-07-16 US disclosed
US-20090179551-A1 Organic Electroluminescent Compounds and Display Device Using the Same GRACEL DISPLAY INC. (KP) 2009-07-16 US disclosed
WO-2007061218-A1 ORGANIC ELECTROLUMINESCENT COMPOUNDS AND DISPLAY DEVICE USING THE SAME GRACEL DISPLAY INC. (KR) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090179551-A1 Organic Electroluminescent Compounds and Display Device Using the Same OCIAD2, OCIAD1, ICOSLG ALDH1A1 394/4885L3MBTL1 2568/4885KDM4E 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.